Increased speed for 1536-well plates without compromising signal-to-noise for multi-mode reader, while fluorescence reader offers top and bottom read and well scanning capability
Molecular Devices has announced the introduction of two new microplate readers, Analyst GT and Gemini EM, for drug discovery and life science research applications.
The Analyst GT is the newest addition to the Analyst family of multi-mode plate readers and offers drug discovery researchers significant improvements in read-time and sensitivity in every plate format and every detection mode.
The Gemini EM adds capabilities to the Gemini fluorescence plate reader that allows it to address the fast growing area of cell-based applications.
Commenting on the launch of these two products, Stephen Oldfield, vice president of marketing at Molecular Devices, noted, "The new GT and EM systems build on the success of our established Analyst and Gemini families.
The thousands of researchers currently using our products will recognise the familiar, robust instrument platforms and benefit from the new performance and functionality in both drug discovery and life science research." The company says that the Analyst family of instruments set the performance standard for multimode systems at introduction in 1997, and in 1998 with the first commercially available 1536 multimode reader. The Analyst GT builds on that reputation with significantly faster read speeds for all plate formats.
Previously, systems that offered 96 through 1536 well compatibility sacrificed read time or sensitivity to read high-density 1536 well plates. Analyst GT improves on existing 1536-well point reading systems by increasing read speed without compromising signal-to-noise and signal-to-background.
The new Gemini EM fluorescence microplate reader system offers top and bottom read and well scanning capability to life science researchers.
The ability to tune wavelengths using the system's dual monochromators enables customers to quickly optimise assays, a feature that has driven the success of the original Gemini product since its introduction in September of 1998.
Scientists can now perform more complex, cell-based assays, which are increasingly used to understand the underlying nature of disease, and develop appropriate therapies.